Predictive Factors for Response to Lutetium-177 PSMA Radioligand Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov) - Oct 8, 2026 - P=N/A | N=70 | Recruiting | Sponsor: Lithuanian University of Health Sciences
Biomarker • New trial • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Adenocarcinoma • Prostate Cancer • Solid Tumor
|